Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

Abstract

The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.

Honey: Another Alternative in the Fight against Antibiotic-Resistant Bacteria?

“…Limiting their use, as much as possible, to those cases that do not respond successfully to existing products leads to a lack of profitability for pharmaceutical companies. In this way, the development of new antimicrobials is no longer an interesting activity [10].…”

Targeted antiviral treatment using non-ionizing radiation therapy for SARS-CoV-2 and viral pandemics preparedness: Technique, methods and practical notes for clinical application

“…Emerging new infective species necessitate development of rapid responses for mitigation and disease control. Conventional responses involving medication(s) providing a treatment through selective biochemical targeting also drive disease resistance [ 1 ] and immunocompromise in the long run; further aggravating overall outcomes of healthcare in disease outbreaks. Effective long-term vaccine/drug development targeting viral components becomes a costly, difficult, sometimes impossible challenge as viruses mutate fast changing their characteristic proteins.…”

Thiosemicarbazide Derivatives Decrease the ATPase Activity of Staphylococcus aureus Topoisomerase IV, Inhibit Mycobacterial Growth, and Affect Replication in Mycobacterium smegmatis

“…The need for novel antibacterial agents to effectively treat drug-resistant infections remains unfulfilled [ 1 , 2 , 3 , 4 , 5 ]. The accumulation of mutations in DNA gyrase and topoisomerase IV genes, jeopardizing the efficacy of fluoroquinolones [ 6 ], is an example of such resistance development and highlights the urgent need to develop novel antibiotic scaffolds.…”